DPT Laboratories, Confab Announce Integration
News Oct 17, 2013
DPT Laboratories has announced the integration of the organizations under the leadership of Paul Johnson, Group President and COO.
Both DPT and Confab are owned by Renaissance Acquisition Holdings, LLC, a portfolio company of RoundTable Healthcare Partners, and represent its CDMO holdings.
The integration includes a re-branding and new logo for Confab, identifying it as a DPT company. A primary focus of the integration is for DPT’s established sales and marketing team to introduce Confab’s specialized expertise in complex solid, semi-solid and liquid dosage forms to new pharmaceutical industry clients, especially in the U.S. market.
The management teams for both companies will remain in place, with Confab development and manufacturing continuing to operate under the direction of President and General Manager Nathalie Brisson.
“Confab is one of the most-respected pharmaceutical outsourcing organizations in Canada, with more than 30 years’ experience in manufacturing, packaging and analyzing a wide range of projects for both large and small pharmaceutical companies,” said Johnson.
“The integration will provide our sales team with complimentary manufacturing capabilities and a broader range of services to offer to our customers,” he added. “At the same time, the increased marketing support will leverage the continued investment Confab has made in infrastructure and capabilities, paying dividends in new client development and increased sales growth.”
Confab has 350 employees and a 140,000-square-foot, cGMP-compliant turnkey facility, which is licensed by the Health Canada Therapeutic Products Directorate, as well as the United States Food and Drug Administration.
“DPT’s sales and marketing team has a proven track record for building client relationships and driving growth,” said Brisson. “For our team at Confab, this will mean broader recognition of our capabilities and services, access to new markets and increased opportunities for growth.”
DPT, the industry leader for semi-solids and liquids, has research and development as well as manufacturing facilities in San Antonio, TX, as well as in Lakewood, N.J., where it is expanding its presence in the sterile and specialty products markets.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019